RT Journal Article SR Electronic T1 Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.05.15.21256814 DO 10.1101/2021.05.15.21256814 A1 Adolfo Aleman A1 Oliver Van Oekelen A1 Bhaskar Upadhyaya A1 Sarita Agte A1 Katerina Kappes A1 Katherine Beach A1 Komal Srivastava A1 Charles R. Gleason A1 PVI study group A1 Bo Wang A1 Tarek H. Mouhieddine A1 Kevin Tuballes A1 Daniel Geanon A1 Zenab Khan A1 Ana S. Gonzalez-Reiche A1 Harm van Bakel A1 Nicole W. Simons A1 Konstantinos Mouskas A1 Alexander W. Charney A1 Adeeb Rahman A1 Seunghee Kim-Schulze A1 Emilia M. Sordillo A1 Florian Krammer A1 Carlos Cordon-Cardo A1 Nina Bhardwaj A1 Sacha Gnjatic A1 Miriam Merad A1 Brian D. Brown A1 Larysa Sanchez A1 Ajai Chari A1 Sundar Jagannath A1 Viviana Simon A1 Ania Wajnberg A1 Samir Parekh YR 2021 UL http://medrxiv.org/content/early/2021/05/15/2021.05.15.21256814.abstract AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are highly effective in healthy individuals. Patients with multiple myeloma (MM) are immunocompromised due to defects in humoral and cellular immunity as well as immunosuppressive therapies. The efficacy after two doses of SARS-CoV-2 mRNA vaccination in MM patients is currently unknown. Here, we report the case of a MM patient who developed a fatal SARS-CoV-2 infection after full vaccination while in remission after B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T treatment. We show that the patient failed to generate antibodies or SARS-CoV-2-specific B and T cell responses, highlighting the continued risk of severe coronavirus disease 2019 (COVID-19) in vaccine non-responders. In the largest cohort of vaccinated MM patients to date, we demonstrate that 15.9% lack SARS-CoV-2 spike antibody response more than 10 days after the second mRNA vaccine dose. The patients actively receiving MM treatment, especially on regimens containing anti-CD38 and anti-BCMA, have lower antibody responses compared to healthy controls. Thus, it is of critical importance to monitor this patient population for serological responses. Non-responders may benefit from ongoing public health measures and from urgent study of prophylactic treatments to prevent SARS-CoV-2 infection.Competing Interest StatementThe Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Viviana Simon is listed on the serological assay patent application as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020) and is currently consulting for Seqirus and Avimex. The Krammer laboratory is collaborating with Pfizer on animal models of SARS-CoV-2. Bo Wang reports consulting fees for Sanofi Genzyme. Ajai Chari reports consulting fees for Takeda, Genzyme, Amgen, Bristol Myers Squibb (Celgene) and Janssen. Sundar Jagannath reports consulting fees for Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Merck, Sanofi, and Takeda Pharmaceuticals. Samir Parekh reports consulting fees from Foundation Medicine. Other authors reported no relevant conflicts of interest.Funding StatementSamir Parekh is supported by National Cancer Institute (NCI) R01 CA244899, CA252222 and receives research funding from Amgen, Celgene/BMS, Karyopharm. This work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C and HHSN272201400006C), NIAID grants U01AI141990 and U01AI150747, by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384); and by anonymous donors. This effort was supported by the Serological Sciences Network (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study cohort consisted of 208 patients with and without previously documented COVID-19 pooled from four different Institutional Review Board (IRB) approved protocols at The Icahn School of Medicine at Sinai. A total of 77 MM patients were enrolled after obtaining written informed consent for an ongoing longitudinal study at our institution (IRB-16-00791). The remaining 131 MM patients were identified under a retrospective study (IRB: GCO#: 11-1433). Control group: 38 participants of the PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2) study were selected as controls. The study was reviewed and approved by the Mount Sinai Hospital Institutional Review Board (IRB-20-03374). All participants provided informed consent prior to collection of data and specimen.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll requests for raw and analyzed data and materials will be promptly reviewed by the Icahn School of Medicine at Mount Sinai and the Mount Sinai Hospital to verify if the request is subject to any confidentiality and data protection obligations. Any data and materials that can be shared will be released via a material transfer agreement.